Seaport Therapeutics, Inc. (SPTX) is an innovative biopharmaceutical company focused on the development of cutting-edge immune-oncology therapies aimed at addressing crucial unmet medical needs, particularly in oncology. Leveraging state-of-the-art technologies and an extensive research pipeline, Seaport is committed to creating targeted treatment options for complex diseases, with a specific emphasis on cancer. The company fosters strategic collaborations that augment its capabilities in the rapidly evolving therapeutics landscape, supported by a seasoned management team dedicated to enhancing patient outcomes. With a strong emphasis on scientific innovation and patient impact, Seaport Therapeutics is strategically positioned to influence the future of cancer treatment and immunotherapy.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-96.02M |
| Operating Margin | 0.00% |
| Return on Equity | -28.10% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-44.55 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.53M |
| Float | $28.29M |
| % Insiders | 35.06% |
| % Institutions | 35.44% |
Volatility is currently contracting
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.
Drug developer Seaport Therapeutics said on Thursday it had raised about $255 million in its upsized initial public offering in the United States.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering.
Drug developer Seaport Therapeutics said on Monday it was aiming for a valuation of $912 million in its initial public offering in the United States.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SPTX and any ticker you trade — then tracks every position and per-strategy win rate.
